Tocilizumabulous? A special offer on IL-6 with Tocilizumab.

It’s very rare we produce three instalments on one particular drug for one particular condition, and certainly not within such a short time frame. However, tocilizumab has been worth it. Maybe not the one intervention to rule them all, but a therapy that despite courting initial controversy, now seems to be emerging with a definitive … Continue reading Tocilizumabulous? A special offer on IL-6 with Tocilizumab.